Advertisement

Topics

Latest "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Stories

14:29 EDT 24th July 2016 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive news archives from over 250 global news sources.

More Information about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine for you to read. Along with our medical data and news we also list autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Companies for you to search.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Articles 1–25 of 15,000+

Extremely Relevant

Prolonged Cell Division Arrest Prevents Development of Cancers Caused by Epstein-Barr Virus

A mechanism has been identified that helps explain why despite most people having been infected with Epstein-Barr virus, very few...


Atara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder

SOUTH SAN FRANCISCO, Calif., March 23, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that the European Medicines Agency (EMA) granted orphan drug designation for the Company’s allogeneic ...

Molecular Methods Compared for Quantitative Detection of Epstein-Barr Virus

Quantitative detection of Epstein-Barr virus by real time polymerase chain reaction (PCR) has become standard of care in the management...


Donor epstein-barr serostatus influences GVHD after allo-HSCT

(HealthDay)—Donor Epstein-Barr virus (EBV) serostatus influences incidence of graft-versus-host disease (GVHD) in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT), according to a study published online April 18 in the Journal of Clinical Oncology.

Epstein-Barr virus and carcinomas: rare association of the virus with gastric adenocarcinomas

BRIEF-Atara biotherapeutics says European Medicines Agency granted orphan drug designation for allogeneic epstein-barr virus targeted cytotoxic t-lymphocyte product candidate

* European Medicines Agency granted orphan drug designation for allogeneic epstein-barr virus targeted cytotoxic t-lymphocyte product candidate

Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD)

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the Compa...

Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns

Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate

SOUTH SAN FRANCISCO, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life threatening diseases that have been underserved by scientific innovation, today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) reported ...

Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA)

SOUTH SAN FRANCISCO, Calif., June 23, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that the EMA has classified the Company’s EBV-CTL product candidate as an Advanced Therapy Medicinal Product (ATMP) that falls within the defini...

Atara Bio Doses First Patient in Multi-Center Expanded Access Protocol for Study of Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) in EBV-Associated Lymphomas and Lymphoproliferative Disorders

SOUTH SAN FRANCISCO, Calif., July 12, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced the dosing of its first patient in the multi-center Expanded Access Protocol (EAP) for Study of Allogeneic EBV-CTLs in EBV-Associated Lymphomas an...

[Articles] Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study

This is the first study providing evidence for Zika virus infection causing Guillain-Barré syndrome. Because Zika virus is spreading rapidly across the Americas, at risk countries need to prepare for adequate intensive care beds capacity to manage patients with Guillain-Barré syndrome.

Zika virus might cause Guillain-Barré syndrome, according to new evidence

Analysis of blood samples from 42 patients diagnosed with Guillain-Barré syndrome (GBS) during the Zika virus outbreak in French Polynesia provides the first evidence that Zika virus might cause GBS, a severe neurological disorder, according to new research. Based on the analysis of data from French Polynesia, if 100,000 people were infected with Zika virus, 24 would develop GBS.

Heart Failure Drug Could Treat Herpes Virus, Suggest Study

Early research suggests the heart failure drug spironolactone hinders infection from the Epstein-Barr virus, a pathogen linked to mono and different types of cancer. Spironolactone is a “potassium-sparing diuretic” that prevents potassium levels from dropping too low and ensures the body doesn’t absorb excess levels of salt. Congestive heart failure patients also take the drug to treat flui...

[Comment] Zika virus: time to move from case reports to case control

Until the French Polynesian outbreak in 2013–14, Zika virus disease was thought to be only a mild disease. During this outbreak, the incidence of Guillain-Barré syndrome was 20 times higher than expected.1 Similarly, the emergence of Zika virus in the Americas since 2015 has been associated with a dramatic increase of reported cases of microcephaly.2 As for Zika virus and Guillain-Barré syndro...

Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines

Heart Failure Drug Could Treat Herpes Virus, Suggests Study

Early research suggests the heart failure drug spironolactone hinders infection from the Epstein-Barr virus, a pathogen linked to mono and different types of cancer. Spironolactone is a “potassium-sparing diuretic” that prevents potassium levels from dropping too low and ensures the body doesn’t absorb excess levels of salt. Congestive heart failure patients also take the drug to treat flui...

LabRoots to Host DiaSorin Webinar That Fills in Common Knowledge Gaps About Epstein-Barr Virus Infection

The Webinar will discuss clinical findings and lab tests for diagnosing and staging primary EBV infection, mechanisms by which it causes cancer and autoimmune diseases, and research aimed at preventing it, May 17, 2016 Yorba Linda, CA (PRWEB) April 25, 2016 Despite the fact that infectious mononucleosis has been known as a unique disease for more than 100 years, and that Epstein-Barr virus—whic...

Scalable Production of Influenza Virus

The future of influenza vaccine production most likely lies with cell culture-based processes. Cell-based systems offer numerous advantages over traditional egg-based production, including speed of production, lack of dependence on egg supply, avoidance of egg allergens, higher initial purity, and ability to combine upstream and downstream into an automated process. Cell culture is well suited...

BRIEF-Atara Bio receives ATMP classification for its EBV-CTLs product candidate from EMA

* Atara Bio receives advanced therapy medicinal product classification for allogeneic epstein-barr virus specific cytotoxic T-Lymphocytes (EBV-CTLs) from European Medicines Agency (EMA) Source text for Eikon: Further company coverage: (Bengaluru...

Origins of the Zika outbreak and its potential threat

Researchers are working to understand more about the Zika virus — how it is transmitted, its link to microcephaly and Guillain-Barré syndrome and whether a vaccine can be developed.

Researchers confirm causal link between Zika virus and Guillain-Barré Syndrome

French researchers suspect that Zika Virus is responsible for the cause of Guillain-Barré Syndrome (GBS), a severe form of limb paralysis that is often accompanied by respiratory impairment requiring intensive care.

Explainer: what is Guillain-Barré syndrome and is it caused by the Zika virus?

Steven Maltby, University of Newcastle The recent outbreak of Zika virus in South America has been a cause of concern. This is not because Zika itself is a serious condition, but because it is believed to be linked to birth defects when expectant mothers are infected and to a rare but severe and progressive neurological […] The post Explainer: what is Guillain-Barré syndrome and is it cause...

Sequencing Predicts Cancer Vaccine's Outcomes

Clinical Informatics News | A new study by UCLA researchers demonstrates the use of next generation sequencing to predict survival of brain cancer patients treated with a cancer vaccine. The vaccine, an autologous dendritic cell therapy called DCVax-L, is under development by Northwest Biotherapeutics Inc., of Bethesda, Md., for glioblastoma multiforme (GBM). It is designed to activate the ad...

[Articles] Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial

Intradermal zoster vaccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with subcutaneous zoster vaccine at comparable doses. Larger and longer studies of intradermal administration of live, attenuated zoster vaccine are needed to provide convincing evidence of improved cell mediated immunity.


Quick Search
Advertisement
 

News Quicklinks